Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Analysis of Reintervention According to the Drug-Eluting Stent Type
(A) Absolute numbers of patients requiring reintervention and hazard ratios (HRs) for this end point with sirolimus-eluting stent (SES) versus paclitaxel-eluting stent (PES) for individual trials and pooled population. The HRs are shown on a logarithmic scale. The size of the square is proportional to the weight of the individual studies, measured as the inverse of the estimated variance of the log HR. (B) Kaplan-Meier curves of reintervention in each of the stent groups for the pooled population. Hazard ratio indicates the HR associated with the SES. BASKET = Basel Stent Kosten Effektivitäts Trial; CI = confidence interval; CORPAL = Drug-Eluting Stents for Complex Lesions: Randomized Rapamycin Versus Paclitaxel trial; ISAR-DESIRE = Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for In-Stent Restenosis trial; ISAR-DIABETES = Intracoronary Stenting and Angiographic Results: Do Diabetic Patients Derive Similar Benefit From Paclitaxel-Eluting and Sirolimus-Eluting Stents trial; ISAR-SMART 3 = Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries Trial; LONG DES II = Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary Lesions trial; PROSIT = Prospective Randomized Trial of Sirolimus- versus Paclitaxel-Eluting Stents for the Treatment of Acute ST-Elevation Myocardial Infarction; REALITY = Prospective, Randomized, Multi-Center Comparison of the Cypher Sirolimus-Eluting and the Taxus Paclitaxel-Eluting Stent Systems trial; SIRTAX = Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization trial; SORT OUT II = Prospective, Multicenter, Large-Scale, Randomized Trial of Paclitaxel- and Sirolimus-Eluting Stents in "Real-World" Lesions trial; TAXI = Prospective Randomized Comparison Between Paclitaxel and Sirolimus Stents in the Real World of Interventional Cardiology trial.
|
